Showing 4641-4650 of 5349 results for "".
- Researchers Discover New Antibiotic That May Fight MRSAhttps://practicaldermatology.com/news/researchers-discover-new-antibiotic-that-may-fight-mrsa/2458282/Researchers at the University of East Anglia (UEA) and the John Innes Centre (JIC) have uncovered a new antibiotic that they say is potent against antibiotic-resistant ‘superbugs’ like methicillin resistant Staphylococcus aureus (MRSA). The researchers isolated
- Rumor Has It Syneron Is Next In Week of Surprising Aquisitionshttps://practicaldermatology.com/news/rumor-has-it-syneron-is-next-in-week-of-surprising-aquisitions/2458286/Hot off the heels of Allergan’s acquisition of Zeltiq and Hologic Inc,’s surprising purchase of Cynosure Inc., media reports are now swirling that British private equity fund Apax Partners is looking to buy Syneron Medical for $350-$400 million. According to Israeli finan
- Hologic to Acquire Cynosurehttps://practicaldermatology.com/news/hologic-to-acquire-cynosure/2458288/Hologic, Inc. and Cynosure, Inc. have signed a definitive agreement for Hologic to acquire all outstanding Cynosure shares for $66.00 per share in cash, which corresponds to an equity value of approximately $1.65 billi
- Ray Canole is New Chief Commercial Officer at Revision Skincarehttps://practicaldermatology.com/news/ray-canole-is-new-chief-commercial-officer-at-revision-skincare/2458287/Revision Skincare has announced the appointment of Ray Canole to the position of Chief Commercial Officer. He has over 15 years of business development and commercial related experience in dermatology-focused organizations and joins Revision from Renaissance Pharma, where he helped
- New From Alastin Skincare: HydraTint ProMineral Broad Spectrum Sunscreen SPF 36https://practicaldermatology.com/news/new-from-alastin-skincare-hydratint-promineral-broad-spectrum-sunscreen-spf-36/2458289/ALASTIN Skincare, Inc. is introducing HydraTint ProMineral Broad Spectrum Sunscreen SPF 36. The lightweight matte formula is oil-free, absorbs quickly and has a tint. It also comprises an air pollution shield to protect skin from environmental aggresso
- Intramuscular Flu Shots May Mitigate Staph Risk In AD Patientshttps://practicaldermatology.com/news/intramuscular-flu-shots-may-be-better-for-ad-patients/2458290/Staphylococcus colonization of atopic dermatitis patients’ skin is associated with a weaker response to intradermal flu shots, according to a new study which suggests that intramuscular flu vaccines may be more effective in this group. The research, funded by the Natio
- Allergan to Acquire ZELTIQ for $2.47 Billionhttps://practicaldermatology.com/news/allergan-to-acquire-zeltiq-for-247-billion/2458291/Allergan plc and ZELTIQ® Aesthetics, Inc. have entered into a definitive agreement under which Allergan has agreed to acquire ZELTIQ for $56.50 per share, or $2.475 billion, subject to customary
- Alma Lasers' Accent Celebrates 10 Years with a New Campaignhttps://practicaldermatology.com/news/alma-lasers-accent-celebrates-10-years-with-a-new-campaign/2458294/Accent Prime is celebrating a 10 year anniversary with a newly launched campaign. Alma Lasers released the first generation of the Accent branded platform in 2007, with the FDA approval, and technologically enhanced it throughout the pas
- ZO Skin Health Introduces Oraser Cellulite Control Creamhttps://practicaldermatology.com/news/zo-skin-health-introduces-oraser-cellulite-control-cream/2458295/ZO Skin Health's new Oraser Cellulite Control is formulated to offer instant firming effects, visibly improve the skin's texture, and reduce the appearance of cellulite. In addition to smoothing skin and diminishing the "orange peel" appearance, the crème also helps impro
- Study Finds Increased Incidence of SCC Among Patients Treated with Biologics for Psoriasishttps://practicaldermatology.com/news/study-find-increased-incidence-of-scc-among-patients-treated-with-biologics-for-psoriasis/2458296/A recent study published in the Journal of the American Academy of Dermatology sought to estimate the overall malignancy rate (excluding non-melanoma skin cancere [NMSC]) and NMSC rate among 5,889 patients with systemically